More context, better questions

Melanotan II is an experimental melanocortin-related peptide promoted online for tanning and other effects. It is distinct from afamelanotide, the ingredient in an approved implant for a rare phototoxicity disorder. Similar names do not establish equivalent selectivity, quality, or regulatory status.

GHK-Cu is a copper-binding tripeptide studied in skin biology and used in cosmetic formulations. The topical cosmetic ingredient and an injected preparation are different exposures. Evidence about one route should not be used to imply that the other has equivalent benefit or safety.

Melanocortin receptor signaling can influence pigmentation and other physiological functions. A compound engaging this system may have effects beyond skin color. Increasing pigmentation is not the same as preventing skin cancer or replacing recommended protection from ultraviolet exposure.

The GHK sequence binds copper, and experiments explore effects on skin-related cellular signaling and tissue remodeling. Copper is a biologically active metal, while the peptide influences its chemical context. Skin penetration, formulation stability, concentration, and delivery method all affect the exposure actually produced by a topical product.

Experimental interest does not establish a favorable benefit-risk balance for cosmetic use. A visible tanning effect is only one observation and cannot answer long-term safety questions. Clinical claims require a characterized preparation, appropriate monitoring, and outcomes that include harms as well as changes in appearance.

Laboratory studies include skin models, cultured cells, and delivery experiments. These can identify possible mechanisms and formulation challenges. A cosmetic claim about appearance is also different from a treatment claim about a wound, a disease, or hair loss. Each needs relevant evidence using the actual finished product.

Consumer reports rarely provide verified identity or systematic adverse-event follow-up. Pigmentation photographs can also hide changes in moles or other lesions that require assessment. Evidence for a different melanocortin drug should not be transferred to Melanotan II merely because both affect the same broad receptor family.

A favorable cell-culture result does not tell readers how large or durable a visible improvement will be. Many cosmetic products contain several active ingredients, making it difficult to attribute an observed effect specifically to GHK-Cu. Before-and-after photographs are vulnerable to differences in lighting, skin care, timing, and image selection.

FDA materials describe important safety concerns and published serious-event reports. Unapproved preparations add risks involving impurities, contamination, and incorrect concentration. New or changing pigmented lesions warrant medical evaluation; they should not be dismissed as a desirable or expected cosmetic result.

Topical irritation or allergy is possible, and damaged skin can change exposure. Injectable GHK-Cu introduces additional concerns that cannot be answered by topical testing. FDA has highlighted limited safety information and possible problems with aggregation and peptide impurities for injectable routes.

Melanotan II is not an FDA-approved tanning medicine. The existence of an approved afamelanotide product does not authorize a Melanotan II injection or nasal spray.

Cosmetic use does not equal FDA approval as a medicine. GHK-Cu should not be marketed as an FDA-approved injectable anti-aging or hair-restoration treatment. The intended claim and route matter when considering regulatory status.